NYSE:NVO - Novo Nordisk A/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$48.19 +0.22 (+0.46 %)
(As of 09/25/2018 04:00 PM ET)
Previous Close$47.97
Today's Range$48.13 - $48.60
52-Week Range$44.28 - $58.37
Volume167,797 shs
Average Volume1.03 million shs
Market Capitalization$116.46 billion
P/E Ratio20.74
Dividend Yield1.37%
Beta0.65
Novo Nordisk A/S logoNovo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk A/S has a research and licensing agreement with DUKE National University Singapore Medical School to develop stem cell-based treatments for chronic heart failure and age-related macular degeneration; and a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVO
CUSIPN/A
Phone45-4444-8888

Debt

Debt-to-Equity RatioN/A
Current Ratio1.17
Quick Ratio0.84

Price-To-Earnings

Trailing P/E Ratio20.74
Forward P/E Ratio19.12
P/E Growth2.52

Sales & Book Value

Annual Sales$16.96 billion
Price / Sales6.94
Cash Flow$2.5964 per share
Price / Cash18.56
Book Value$3.10 per share
Price / Book15.55

Profitability

EPS (Most Recent Fiscal Year)$2.34
Net Income$5.79 billion
Net Margins35.95%
Return on Equity83.32%
Return on Assets39.88%

Miscellaneous

Employees42,076
Outstanding Shares2,443,530,000
Market Cap$116.46 billion

Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S declared a special dividend on Thursday, August 9th. Stockholders of record on Monday, August 20th will be paid a dividend of $0.4669 per share on Tuesday, August 28th. This represents a dividend yield of 1.72%. The ex-dividend date of this dividend is Friday, August 17th. View Novo Nordisk A/S's Dividend History.

How will Novo Nordisk A/S's stock buyback program work?

Novo Nordisk A/S announced that its Board of Directors has authorized a share repurchase plan on Friday, February 2nd 2018, which authorizes the company to buyback shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Stock buyback plans are generally a sign that the company's board of directors believes its stock is undervalued.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) announced its earnings results on Wednesday, August, 8th. The company reported $0.68 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.04. The business earned $4.39 billion during the quarter, compared to analysts' expectations of $4.33 billion. Novo Nordisk A/S had a return on equity of 83.32% and a net margin of 35.95%. View Novo Nordisk A/S's Earnings History.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for Novo Nordisk A/S.

What is the consensus analysts' recommendation for Novo Nordisk A/S?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novo Nordisk A/S.

Who are some of Novo Nordisk A/S's key competitors?

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the folowing people:
  • Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 52)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 58)
  • Mr. Jesper Brandgaard, Exec. VP and Head of Biopharm & Legal Affairs (Age 55)
  • Ms. Liselotte Hyveled, Former Project VP for Faster-Acting Insulin Aspart & Prandial Bioedge Projects - Insulin & Director (Age 52)
  • Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 46)

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.78%), Fisher Asset Management LLC (0.56%), Bank of America Corp DE (0.50%), BlackRock Inc. (0.37%), Everett Harris & Co. CA (0.13%) and Northern Trust Corp (0.09%). View Institutional Ownership Trends for Novo Nordisk A/S.

Which institutional investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, FMR LLC, BlackRock Inc., Bank of America Corp DE, Orbimed Advisors LLC, Glenmede Trust Co. NA, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA and Hikari Power Ltd. View Insider Buying and Selling for Novo Nordisk A/S.

Which institutional investors are buying Novo Nordisk A/S stock?

NVO stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Envestnet Asset Management Inc., First Trust Advisors LP, Fisher Asset Management LLC, Caisse DE Depot ET Placement DU Quebec, Advisors Asset Management Inc., Wells Fargo & Company MN and Cornerstone Wealth Management LLC. View Insider Buying and Selling for Novo Nordisk A/S.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $48.19.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $116.46 billion and generates $16.96 billion in revenue each year. The company earns $5.79 billion in net income (profit) each year or $2.34 on an earnings per share basis. Novo Nordisk A/S employs 42,076 workers across the globe.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is http://www.novonordisk.com.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]


MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  250 (Vote Outperform)
Underperform Votes:  335 (Vote Underperform)
Total Votes:  585
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel